Online inquiry

IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14534MR)

This product GTTS-WQ14534MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13&IL4 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001354991.2; NM_000589.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596; 3565
UniProt ID P35225; P05112
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14534MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5900MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ13078MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ15089MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ4670MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ10132MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LAG-525
GTTS-WQ8941MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ738MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AAB-001
GTTS-WQ2234MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aVWF81
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW